Origin Materials (ORGN) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
6 Jan, 2026Executive summary
Special Meeting scheduled for February 17, 2026, to be held virtually for shareholder convenience.
Two key proposals: a reverse stock split and approval for issuance of shares upon conversion of senior secured convertible notes.
Board recommends voting in favor of both proposals to maintain Nasdaq listing and enable further capital raising.
Voting available via internet, phone, or mail, with detailed instructions provided to all shareholders.
Voting matters and shareholder proposals
Proposal 1: Approve amendment to certificate of incorporation for a reverse split of common stock at a ratio between 1-for-2 and 1-for-50, at board's discretion.
Proposal 2: Approve issuance of more than 20% of outstanding shares upon conversion of senior secured convertible notes, removing the current share cap.
Board recommends voting "FOR" both proposals.
Only shareholders of record as of December 22, 2025, are entitled to vote.
Quorum is one-third of outstanding shares; each share equals one vote.
Board of directors and corporate governance
Board retains discretion to determine the reverse split ratio and whether to implement it within one year of approval.
Board may abandon the reverse split even if approved by shareholders.
No dissenter's rights are provided for the reverse split.
Latest events from Origin Materials
- Stockholders approved a reverse split and major share issuance, advancing strategic milestones.ORGN
EGM 202618 Feb 2026 - $100M+ PET cap deal signed; Q2 loss $19.5M; Q4 2024 production on track.ORGN
Q2 20241 Feb 2026 - Strong PET cap demand, $100M+ MOU, and EBITDA positivity targeted for 1H 2026.ORGN
Q3 202414 Jan 2026 - Rapid transformation to PET caps leverages technical strengths, innovation, and scalable growth.ORGN
Fireside Chat9 Jan 2026 - Key votes on reverse stock split and major share issuance set for February 2026.ORGN
Proxy Filing6 Jan 2026 - Commercial PET cap production launched; 2026 revenue projected at $110M–$140M, EBITDA positive by year-end.ORGN
Q4 202426 Dec 2025 - Approval sought for reverse split and share issuance to support listing and financing.ORGN
Proxy Filing23 Dec 2025 - High demand and technical leadership drive confidence in growth and successful CapFormer deployment.ORGN
Investor Q&A19 Dec 2025 - Commercial PET cap production and revenue ramping up, with major growth expected by 2026.ORGN
Investor Q&A19 Dec 2025